Nanoparticles in Cancer Treatment: Opportunities and Obstacles

被引:148
作者
Awasthi, Rajendra [1 ]
Roseblade, Ariane [2 ]
Hansbro, Philip Michael [2 ,3 ]
Rathbone, Michael John [4 ]
Dua, Kamal [2 ,5 ]
Bebawy, Mary [2 ]
机构
[1] NKBR Coll Pharm & Res Ctr, Meerut 45206, Uttar Pradesh, India
[2] Univ Technol Sydney, Grad Sch Hlth, Discipline Pharm, Sydney, NSW, Australia
[3] Univ Newcastle, Hunter Med Res Inst, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia
[4] ULTI Pharmaceut, Hamilton 3204, New Zealand
[5] Shoolini Univ, Sch Pharmaceut Sci, Solan 173229, Himachal Prades, India
关键词
Cancer; carbon nanotube; cellular targeting; chemotherapy; diagnostics; extracellular vesicles; MicroRNA; microparticles; multidrug resistance; nanomedicine; nanoprarticles; P-glycoprotein; SOLID LIPID NANOPARTICLES; MESOPOROUS SILICA NANOPARTICLES; OVERCOME DRUG-RESISTANCE; SMALL INTERFERING RNA; P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; BREAST-CANCER; IN-VITRO; MAGNETIC NANOPARTICLES; INTERCELLULAR TRANSFER;
D O I
10.2174/1389450119666180326122831
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the United States, the estimated number of new cancer cases in 2018 will be approx. 1.7 million. Historically, combination chemotherapy has been the primary choice of treatment. However, chemotherapeutics have pharmaceutical limitations, among which include problems with stability and aqueous solubility. Likewise, dose limiting toxicity is significant with nonspecific toxicity to healthy cells, hair loss, loss of appetite, peripheral neuropathy and diarrhea being typical side effects. The emergence of Multidrug resistance (MDR) also presents s a significant challenge for the successful treatment of cancer whereby cancer cells become cross resistant to many of the chemotherapeutic agents used. Nanotechnology presents a new frontier for cancer treatment. It holds potential in minimizing systemic toxicity through the development of functionalized particles for targeted treatment. They also provide an alternative strategy to circumvent multidrug resistance as they have a capacity to by- pass the drug efflux mechanism associated with this phenotype. Aside from the advantages they offer in treatment, nanoparticles are also emerging to be valuable diagnostic entities. This article highlights the various ways nanotechnology is being used to improve the treatment and management of cancer. We also discuss the opportunities and obstacles in this area and provide an up to date review of progress in the treatment of cancer.
引用
收藏
页码:1696 / 1709
页数:14
相关论文
共 185 条
[1]   Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy [J].
Acharya, Sarbari ;
Dilnawaz, Fahima ;
Sahoo, Sanjeeb K. .
BIOMATERIALS, 2009, 30 (29) :5737-5750
[2]   Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression [J].
Aleku, Manuela ;
Schulz, Petra ;
Keil, Oliver ;
Santel, Ansgar ;
Schaeper, Ute ;
Dieckhoff, Britta ;
Janke, Oliver ;
Endruschat, Jens ;
Durieux, Birgit ;
Roeder, Nadine ;
Loeffler, Kathrin ;
Lange, Christian ;
Fechtner, Melanie ;
Moepert, Kristin ;
Fisch, Gerald ;
Dames, Sibylle ;
Arnold, Wolfgang ;
Jochims, Karin ;
Giese, Klaus ;
Wiedenmann, Bertram ;
Scholz, Arne ;
Kaufmann, Joerg .
CANCER RESEARCH, 2008, 68 (23) :9788-9798
[3]   Cellular Heterogeneity and Molecular Evolution in Cancer [J].
Almendro, Vanessa ;
Marusyk, Andriy ;
Polyak, Kornelia .
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 8, 2013, 8 :277-302
[4]  
[Anonymous], CURRENT MED RES OPIN
[5]  
[Anonymous], POLYM NANOPARTICLES
[6]  
[Anonymous], 2011, J NANOMED NANOTECHNO
[7]  
[Anonymous], CURR PHARM DESIGN
[8]  
[Anonymous], NCI ALLIANCE NANOTEC
[9]  
[Anonymous], NEUROONCOL
[10]  
[Anonymous], [No title captured]